Researchers in Dr. Karl Deisseroth's lab have engineered a channelrhodopsin variant that can be stimulated by red light and has fast stimulation frequencies. In neurons, channelrhodopsins are light activated protein channels that induce action potential firing.
Researchers in Prof. Michelle Monje-Deisseroth's laboratory have discovered a previously unknown mechanism for glioma tumor growth and invasion that defines a novel set of therapeutic targets.
To better understand how the brain processes information and generates behavior, researchers in Dr. Liqun Luo's lab have generated the FosTRAP and ArcTRAP mouse strains.
Researchers in Dr. Karl Deisseroth's lab have created inhibitory channelrhodopsins (ChRs) that allow fast, reversible inhibition of electrical signals in neurons. Optogenetics is a technique used to understand normal and pathological neural circuitry.
Researchers in Dr. Shatz's lab have identified murine PirB and its human ortholog LilrB2 as receptors for β-amyloid (Aβ) oligomers. Aβ oligomers play a central role in a number of pathologies.
Researchers in Prof. Karl Deisseroth's laboratory have developed a system to enhance optogenetic pumps using one tool to address current limitations in both inhibition and excitation.
Researchers in Prof. Robert Malenka's laboratory have developed a light-activated animal system that could be used to identify compounds that treat certain psychiatric disorders.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Stanford and Rockefeller researchers have identified and developed dynein-specific inhibitors that have significant medical applications involving mitotic spindle assembly, organelle transport, and primary cilia formation.